OptimizeRx (OPRX) Corporate presentation summary

Platform and market position

• Connects life sciences, HCPs and patients across a network of 2M+ HCPs, 240M+ patients, 300+ EHRs and ~400 brands; reaches top 20 pharma.

• ~130 employees across the U.S. and Croatia; average revenue per FTE of $750K.

• DAAP delivers predictive, privacy-safe targeting across clinical and personal channels; typical deals range from $0.5M to $1.5M.

• Programmatic expansion targets access to ~90% of U.S. digital display spend, including authenticated EHR inventory via direct DSP integration; pharma digital ad market cited at $19B+.

Commercial impact and market opportunity

• Rare disease five-month program: 16% of exposed HCPs wrote brand prescriptions, 50 new high-value scripts and 9% demand lift per exposed HCP.

• Oncology three-month pilot: EHR plus social delivered 33% script lift, 44% more physicians reached, 142% greater script impact than single-tactic execution and 1K+ incremental scripts.

• Supports ~350 brands and covers 45% of the top 200; existing-brand opportunity estimated at $2B-$3B, with ~10% DAAP penetration.

• U.S. pharma digital ad spend chart shows growth from $15.0B in 2022 to $21.6B in 2026.

Financial performance and outlook

• Q2 2026 revenue was $20.5M, GAAP net loss was $0.7M and adjusted EBITDA was $4.9M.

• FY2026 guidance: revenue of $95M-$100M and adjusted EBITDA of $21M-$25M.

• Revenue grew at a 39% CAGR from 2011 to 2025.

• At June 30, 2026, cash and cash equivalents, including short-term investments, were $24.1M; total debt was $19.0M.